Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation

BACKGROUND: Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-versus-host disease (GVHD). We analyzed the assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Saberian, Chantal, Abdel-Wahab, Noha, Abudayyeh, Ala, Rafei, Hind, Joseph, Jacinth, Rondon, Gabriela, Whited, Laura, Gruschkus, Stephen, Fa'ak, Faisal, Daher, May, Knape, Cristina, Safa, Houssein, Shoukier, Mahran, Suarez-Almazor, Maria E, Marcotulli, Megan, Ludford, Kaysia, Gulbis, Alison M, Konopleva, Marina, Ohanian, Maro, Ravandi, Farhad, Garcia-Manero, Guillermo, Oran, Betul, Popat, Uday R, Mehta, Rotesh, Alousi, Amin M, Daver, Naval, Champlin, Richard, Diab, Adi, Al-Atrash, Gheath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919586/
https://www.ncbi.nlm.nih.gov/pubmed/33637601
http://dx.doi.org/10.1136/jitc-2020-001818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919586/
https://www.ncbi.nlm.nih.gov/pubmed/33637601
http://dx.doi.org/10.1136/jitc-2020-001818

Ejemplares similares